Biography
Michael has an MA (by Research and Thesis) and PhD from the interdisciplinary Institute for Science and Society (ISS) at the University of Nottingham. He also holds a BSc in Biology from the University of St. Andrews (2000). Michael currently leads the ESRC funded project 'Biomodifying technologies and experimental space’, which brings together researchers from the Universities of Oxford, Sussex and York. This project examines three '‘gateway technologies’ with wide-ranging applications in medicine and the life sciences; gene editing, induced pluripotent stem cells, and 3D printing of living material. Each of these technologies enables researchers to modify living biological tissue in novel and increasingly patient-orientated and customized ways, which challenge the suitability of traditional manufacturing, governance and reimbursement pathways designed for small molecule pharmaceuticals or medical devices.
Michael has previously worked on the IMI STEMBANCC project, providing governance and ethical support to this European public-private partnership in stem cell biobanking. He has also been a researcher on the European Framework Programme 7 'Regenerative Medicine in Europe' (REMEDiE) project at the University of York and with the Health Technology and Society group at the University of Exeter.
Publications
Displaying 1 - 31 of 31. Sorted by year, then title.
-
M Morrison, HJA Teare and G Bertier and others, 'Implications of secondary findings for clinical contexts' in M Langanke| P Erdmann| K Brothers (ed), Secondary Findings in Genomic Research (Elsevier 2020) -
M Morrison, M Mourby and A Bartlett, 'Biomodifying technologies and experimental space: organisational and regulatory implications for the translation and valuation of health research' (2019) ESRC 63 DOI: 10.21820/23987073.2019.1.63M Morrison and S de Saille, 'CRISPR in context: towards a socially responsible debate on embryo editing.' (2019) 5 Palgrave Communications DOI: 10.1057/s41599-019-0319-5M Morrison, J Bell and R Isasi, 'Chapter 2: stem cell use' (2018) Genotoul Societal Governing Stem cells Regenerative medicine in Europe: the vision and recommendations from the EU CelLEX project J Kaye, SF Terry, E Jeungst and M Morrison and others, 'Including all voices in international data-sharing governance' (2018) 12 Human Genomics 13 DOI: 10.1186/s40246-018-0143-9M Morrison, 'Making Cells Worthwhile: Calculations of Value in a European Consortium for Induced Pluripotent Stem Cell Banking' (2018) Science as Culture 46 DOI: 10.1080/09505431.2018.1538331O Feeney, J Cockbain and M Morrison, 'Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies' (2018) The American Journal of Bioethics 36 DOI: 10.1080/15265161.2018.1531160J Minari, K Brothers and M Morrison, 'Tensions in ethics and policy created by National Precision Medicine Programs' (2018) Human Genomics DOI: 10.1186/s40246-018-0151-9M Morrison, 'Valuing height: diagnosis, valuation and the case of idiopathic short stature' (2018) 41 Sociology of Health & Illness 502 DOI: 10.1111/1467-9566.12828M Morrison, 'A good collaboration is based on unique contributions from each side: assessing the dynamics of collaboration in stem cell science' (2017) 13 Life Sciences, Society and Policy 7 DOI: 10.1186/s40504-017-0053-yM Morrison, 'Infrastructural expectations: exploring the promise of international large-scale induced pluripotent stem cell banks' (2017) New Genetics and Society 66 DOI: 10.1080/14636778.2017.1289470D Nicol, L Eckstein and M Morrison and others, 'Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic' (2017) 9 Genomic Medicine 85 DOI: 10.1186/s13073-017-0475-4M F. Bin Abdul Azi, M Morrison and J Kaye, 'Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives' (2017) New Genetics and Society 43862 DOI: 10.1080/14636778.2017.1415137M Morrison, J Bell and C George, 'The European General Data Protection Regulation: Challenges and considerations for iPSC researchers and biobanks' (2017) 12 Regenerative Medicine 693 DOI: 10.2217/rme-2017-0068L Bezuidenhout and M Morrison, 'Between Scylla and Charybdis: reconciling competing data management demands in the life sciences' (2016) 17 BMC Medical Ethics 74 DOI: 10.1186/s12910-016-0112-6M Morrison, D Dickenson and SS_J Lee, 'Introduction to the article collection 'Translation in healthcare: Ethical, legal, and social implications' (2016) 17 BMC Medical Ethics 29 DOI: 10.1186/s12910-016-0157-6M Morrison, 'Overdiagnosis, medicalisation and social justice: commentary on Carter et al (2016) ‘A definition and ethical evaluation of overdiagnosis’' (2016) 42 Journal of Medical Ethics DOI: 10.1136/medethics-2016-103717M Morrison, C Klein and N Clemann and others, 'StemBANCC: Governing access to material and data in a large stem cell research consortium' (2015) 11 Stem Cell Reviews and Reports 681 DOI: 10.1007/s12015-015-9599-3M Morrison, 'STS and enhancement technologies: A programme for future research' (2015) 28 Science and Technology Studies H Teare, M Morrison and EA Whitley, 'Towards 'Engagement 2.0': Insights from a study of dynamic consent with biobank participants' (2015) 1 Digital Health DOI: 10.1177/2055207615605644M Morrison, LB Moraia and JC Steele, 'Traceability in stem cell research: From participant sample to induced pluripotent stem cell and back' (2015) 11 Regenerative medicine 73 DOI: 10.2217/rme.15.66J Kaye, EA Whitley, D Lund and M Morrison, 'Dynamic consent: A patient interface for twenty-first century research networks' (2014) 23 European Journal of Human Genetics DOI: 10.1038/ejhg.2014.71M Morrison, 'Growth hormone, enhancement and the pharmaceuticalisation of short stature' (2014) 44 Social science & medicine DOI: 10.1016/j.socscimed.2014.10.015K Melham, LB Moraia, C Mitchell and M Morrison, 'The evolution of withdrawal: negotiating research relationships in biobanking' (2014) 10 Life Sciences, Society and Policy DOI: 10.1186/s40504-014-0016-5M Morrison, S Hogarth and B Kewell, 'Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine' in Andrew Webster (ed), The Global Dynamics of Regenerative Medicine: A Social Science Critique (Palgrave Macmillan 2013) DOI: 10.1057/9781137026552_3M Morrison, 'Me medicine vs. we medicine: reclaiming biotechnology for the common good' (2013) 32 New Genetics and Society DOI: 10.1080/14636778.2013.850025M Morrison and L Cornips, 'Exploring the Role of Dedicated Online Biotechnology News Providers in the Innovation Economy' (2012) 37 Science, Technology, & Human Values DOI: 10.2307/41511174M Morrison, 'Promissory futures and possible pasts: The dynamics of contemporary expectations in regenerative medicine BioSocieties' (2012) 7 BioSocieties DOI: 10.1057/biosoc.2011.24G Bahadur, M Morrison and L Machin, 'Beyond the 'embryo question': Human embryonic stem cell ethics in the context of biomaterial donation in the UK' (2010) 21 Reproductive biomedicine online DOI: 10.1016/j.rbmo.2010.10.001G Bahadur and M Morrison, 'Patenting human pluripotent cells: Balancing commercial, academic and ethical interests' (2009) 25 Human reproduction (Oxford, England) DOI: 10.1093/humrep/dep369P A Martin and M Morrison, Realising the potential of genomic medicine (Royal Pharmaceutical Society of Great Britain; London 2006) Research programmes
Research projects
- BioGOV: Governing Biomodification in the Life Sciences
- Biomodifying Technologies
- CitizenHealthOxford
- DIRECT
- Dynamic Consent
- Embedding Biobanks as Tools for Translational Research
- Governance of Health Data in Cyberspace
- The Waiting Room Project
Research Interests
Michael’s primary research interest and expertise lies in the application of insights and perspectives from Science and Technology Studies (STS) and medical sociology to the study of novel and emerging biotechnologies. More specifically, he is concerned with understanding the ways in which these technologies are shaped by a variety of social factors – including institutional and regulatory cultures as well as the perspectives of developers and prospective users – throughout the course of their development and deployment into practice; and how, in turn, new biomedical technologies shape and reconfigure our understandings of disease, health, and the ‘sorts’ of people we are or can be. He is also working with Jane Kaye and other HeLEX members to develop novel consent procedures for large-scale biobanking projects.
Research projects